Ireland Cancer Center and TRACON Pharmaceuticals Announce Treating the First Cancer Patient With TRC102, An Inhibitor of Chemotherapy Resistance CLEVELAND and SAN DIEGO, Feb. 25, 2008 (PRIME NEWSWIRE) -- The Ireland Cancer Center of University Hospitals Case Medical Center and TRACON Pharmaceuticals, Inc. announced that the first cancer...

TRACON Pharmaceuticals Announces Dosing of Initial Three Cancer Patients in a Phase 1 Clinical Trial With TRC105, a Human Chimeric Antibody SAN DIEGO, Jan. 9, 2008 (PRIME NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (TRACON), a privately-held biopharmaceutical company focused on the development of products for oncology and ophthalmology...

TRACON Pharmaceuticals to Present At the Rodman & Renshaw 9th Annual Healthcare Conference SAN DIEGO, Nov. 2, 2007 (PRIME NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (TRACON), a biopharmaceutical company focused on the development of products for oncology and ophthalmology treatment, today...